Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Promising outcomes reported for transcatheter mitral valve-in-valve replacement

The overall procedural technical success rate, researchers reported, was 96.8%.

Thumbnail

CV societies ‘very concerned’ about proposed coverage changes for MR therapy

The American College of Cardiology, Society of Thoracic Surgeons, American Association for Thoracic Surgery and Society for Cardiovascular Angiography and Interventions all collaborated on the response. 

Worth the wait: After years of trying, researchers 3D print a working heart pump with human cells

The model sits at approximately 1.5 cm long and offers researchers a new way to observe the heart in motion.

Thumbnail

Outcomes ‘worse than expected’ when TAVR fails and surgery is required

The mortality rate was 17% for patients undergoing SAVR following a failed TAVR. 

Thumbnail

CMS proposes coverage updates, and a name change, for TMVR

CMS has proposed expanding its national coverage policy for transcatheter edge-to-edge repair of the mitral valve so that it includes patients with functional mitral regurgitation. 

New polymer heart valve could be a breakthrough for valve replacement surgery

The artificial valve would give clinicians a new option that lasts up to 25 years and does not require prescribing anticoagulation medications.

Thumbnail

Outcomes continue to be favorable for low-risk TAVR patients receiving self-expanding valve

Low-risk transcatheter atortic valve replacement (TAVR) patients with aortic stenosis who receive the Evolut PRO continue to experience outcomes comparable to surgery.

Thumbnail

Sapien 3 TAVR outcomes comparable to surgery after 5 years

Transcatheter aortic valve replacement (TAVR) with the Sapien 3 prosthesis achieved five-year clinical outcomes similar to surgical aortic valve replacement (SAVR).

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.